

Curriculum Vitae

Tan A. Ince, M.D., Ph.D.

1. June 19, 2015

I. Higher Education

2. Institutional:

Ph.D. - Pharmacology
Cornell University, New York, NY 09/1989-01/1996

M.D.
Hacettepe University School of Medicine
Ankara, Turkey 07/1982-06/1988

3. Non-Institutional:

Fellowship - Women's and Perinatal Pathology
Brigham and Women's Hospital, Harvard Medical School, MA 07/2000-06/2001

Residency - Anatomic Pathology
Massachusetts General Hospital, Harvard Medical School, MA 07/1998-06/2000

4. Certification and Licensure:

Florida Medical License
Department of Health, Division of Medical Quality Assurance
State of Florida July 2010

Massachusetts Medical License
Board of Registration in Medicine
The Commonwealth of Massachusetts June 2001

Indiana Medical License May 2001 - June 2003

Anatomic Pathology
The American Board of Pathology September 2001

ECFMG Certificate September 1991

II. Experience

5. Academic:

University of Miami Miller School of Medicine
Associate Professor of Pathology 05/2010-present

Curriculum Vitae

Tan A. Ince, M.D., Ph.D.

Harvard Medical School
Assistant Professor of Pathology 05/2008-05/2010

Harvard Medical School
Instructor in Pathology 07/2001-05/2008

6. *Hospital Appt:*

Brigham and Women's Hospital
Associate Pathologist 05/2008-05/2010

Brigham and Women's Hospital
Assistant Pathologist 07/2001-05/2008

Harvard Medical School
Clinical Fellow in Pathology 07/1998-06/2001

7. *Non-Academic:*

Visiting Clinical Scientist - Molecular Oncology
Whitehead Institute, Massachusetts Institute
of Technology, MA 07/2001-07/2007

III. Publications

8. *Books and Monographs Published:*

1. Mutter GM and **Ince TA**. Tumors of the Female Genital Tract (B), Endometrium, in Diagnostic Histopathology of Tumors, Ed. Christopher D. M. Fletcher, Churchill Livingstone; 3 Edition Vol 1, p. 652-671; April 2007

2. Mutter, GL and **Ince TA**. Molecular Pathogenesis of Endometrial Cancer. p. 10-21; In: Filler AF, Seiden MV and Young R, eds. Uterine Cancer: ACS Atlas of Clinical Oncology Ontario: BC Decker Inc. 2004

3. **Ince TA**, Scotto KW. Transcriptional regulation of multidrug-resistant genes. Vol III. p. 1751-64; In: Bertino JR, editor. Encyclopedia of Cancer. San Diego: Academic Press, Inc. 1997

9. *Juried or Refereed Journal Articles or Exhibitions:*

1. **Ince TA**, Sousa AD, Jones MA, Harrell JC, Agoston ES, Krohn M, Selfors LM, Liu W, Chen K, Yong M, Buchwald P, Wang B, Hale KS, Cohick E, Sergeant P, Witt A, Kozhekbaeva Z, Gao S, Agoston AT, Merritt MA, Foster R, Rueda BR, Crum CP, Brugge JS, Mills GB. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Communications. 2015 Jun 17:6:7419. doi:10.1038/ncomms8419.

Curriculum Vitae

Tan A. Ince, M.D., Ph.D.

PubMed Central PMID: 26080861

2. Houseman EA, **Ince TA**. Normal cell-type epigenetics and breast cancer classification: a case study of cell mixture-adjusted analysis of DNA methylation data from tumors. *Cancer Inform.* 2014 Dec 9;13(Suppl 4):53-64. doi: 10.4137/CIN.S13980. eCollection 2014. PubMed PMID: 25574126; **PubMed Central PMCID: PMC4264613**.
3. Santagata S, **Ince TA**. Normal cell phenotypes of breast epithelial cells provide the foundation of a breast cancer taxonomy. *Expert Rev Anticancer Ther.* 2014 Dec;14(12):1385-9. doi: 10.1586/14737140.2014.956096. Epub 2014 Sep 27. **PubMed PMID: 25263303**.
4. Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, **Ince TA**, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. *Jun 2;124(6):2611-25.* doi: 10.1172/JCI69815 **J Clin Invest. 2014**
5. Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, Hu R, Harrell JC, McNamara G, Schwede M, Culhane AC, Kindelberger D, Rodig S, Richardson A, Schnitt SJ, Tamimi RM, **Ince TA**. Taxonomy of breast cancer based on normal cell phenotype predicts outcome. *Feb 3;124(2):859-70.* pii: 70941. doi: 10.1172/JCI70941. **J Clin Invest. 2014**

Highlighted in:

- At last: classification of human mammary cells elucidates breast cancer origins Robert D. Cardiff, Alexander D. Borowsky 124(2):478-480. doi:10.1172/JCI73910 **J Clin Invest., 2014**
 - Breast cancer classification, Gemma K. Alderton, 14, 155, doi:10.1038/nrc3697 **Nature Reviews Cancer, 2014**
 - A Novel Ontogeny-Based Breast Cancer Classification. Highlights from Recent Cancer Literature. March 15, 74; 1623 **Cancer Res., 2014**
6. Kim KJ, Godarova A, Seedle K, Kim MH, **Ince TA**, Wells SI, Driscoll JJ, Godar S. Rb Suppresses Collective Invasion, Circulation and Metastasis of Breast Cancer Cells in CD44-Dependent Manner. *Dec 4;8(12):e80590.* doi: 10.1371/journal.pone.0080590. eCollection 2013. **PLOS ONE, 2013**
 7. MA. Merritt, S Bentink, M Schwede, MP. Iwanicki, J Quackenbush, T Woo, ES. Agoston, CP. Crum, RS. Berkowitz, S C. Mok, AE. Witt, MA. Jones, B Wang and **TA. Ince**. Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomes. *Nov 26;8(11):e80314.* doi: 10.1371 **PLOS ONE, 2013**
 8. Fabio Petrocca, Gabriel Altschuler, Gregory Idos, Mynn Tan, Elizabeth O'Day, Sean Johnston, Stewart Rudnicki, Caroline Shamu, Winston Hide, **Tan Ince** and Judy Lieberman. A genome-wide

Curriculum Vitae

Tan A. Ince, M.D., Ph.D.

- siRNA screen identifies selective inhibitors of triple-negative breast tumor-initiating cell. Aug 12;24(2):182-96, **Cancer Cell, 2013**
9. Helin Vakifahmetoglu-Norberg, Minsu Kim, Hong-guang Xia, Marcin P. Iwanicki, Dmitry Ofengeim, Jonathan L. Coloff, Lifeng Pan, **Tan A. Ince**, Guido Kroemer, Joan S. Brugge and Junying Yuan. Chaperone Mediated Autophagy Degrades Mutant p53. Aug 1;27(15):1718-30 **Genes & Development, 2013.**
 10. Wander SA, Zhao D, Besser AH, Hong F, Wei J, **Ince TA**, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Apr;138(2):369-81, **Breast Cancer Res Treat., 2013**
 11. Cherry AB, Gagne KE, McLoughlin EM, Baccei A, Gorman B, Hartung O, Miller JD, Zhang J, Zon RL, **Ince TA**, Neufeld EJ, Lerou PH, Fleming MD, Daley GQ, Agarwal S. Induced Pluripotent Stem Cells with a Pathological Mitochondrial DNA Deletion. 31: 1287–1297, **Stem Cells, July 2013**
 12. Yost AJ, Shevchuk OO, Gooch R, Gusscott S, You MJ, **Ince TA***, Aster JC, Weng AP*. Defined, serum-free conditions for in vitro culture of primary human T-ALL blasts. Jun;27(6):1437-40. **Leukemia, 2013.** *Corresponding author
 13. Mendillo ML, Santagata S, Koeva M, Bell GW, Hu R, Tamimi RM, Fraenkel E, **Ince TA**, Whitesell L, Lindquist S. HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers. 150(3):549-62, **Cell, 2012**
 14. Usubutun A, Mutter GL, Saglam A, Dolgun A, Ozkan EA, **Ince TA**, Akyol A, Bulbul HD, Calay Z, Eren F, Gumurdulu D, Haberal AN, Ilvan S, Karaveli S, Koyuncuoglu M, Muezzinoglu B, Muftuoglu KH, Ozdemir N, Ozen O, Baykara S, Pestereli E, Ulukus EC, Zekioglu O. Reproducibility of endometrial intraepithelial neoplasia diagnosis is good, but influenced by the diagnostic style of pathologists. 25(6):877-84, **Mod Pathol., 2012**
 15. Simpkins FA, Hevia-Paez P, Sun J, Ullmer W, Gilbert C, da Silva T, Pedram A, Levin E, Reis I, Rabinovich B, Azzam D, Xu XM, **Ince TA**, Yang JY, Verhaak R, Lu Y, Mills GB, Slingerland JM. Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Nov 1;18(21):5911-23, **Clin Cancer Res., 2012**
 16. Santagata S, Hu R, Lin NU, Mendillo ML, Collins LC, Hankinson SE, Schnitt SJ, Whitesell L, Tamimi RM, Lindquist S, **Ince TA**. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Nov 8; 108(45):18378-83, **Proc Natl Acad Sci., 2011**
 17. Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, Danuser G, **Ince TA** and Brugge JS. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Jul;1(2):144-57, **Cancer Discovery, 2011**

Curriculum Vitae

Tan A. Ince, M.D., Ph.D.

18. Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Cameron MJ, West NH, Agoston ES, Reynoird N, Khochbin S, **Ince TA**, Christie A, Janeway KA, Vargas SO, Perez-Atayde AR, Aster JC, Sallan SE, Kung AL, Bradner JE, French CA. Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming. 1;71 (7):2686-96, **Cancer Res., 2011**
19. Chan EM, Ratanasirintrawoot S, Park IH, Manos PD, Loh YH, Huo H, Miller JD, Hartung O, Rho J, **Ince TA**, Daley GQ, Schlaeger TM. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. 27(11):1033-7; **Nat Biotechnol., 2009**
20. Elmasri H, Karaaslan C, Teper Y, Ghelfi E, Weng M, **Ince TA**, Kozakewich H, Bischoff J, Cataltepe S. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. 23(11):3865-73; **FASEB J., 2009**
21. Lin MC, Lomo L, Baak JP, Eng C, **Ince TA**, Crum CP, Mutter GL. Squamous morules are functionally inert elements of premalignant endometrial neoplasia. 22(2): 167-74; **Mod Pathol., 2009**
22. Jarboe EA, Folkins AK, Drapkin R, **Ince TA**, Agoston ES, Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology. 2009 Nov;55(5):619. doi: 10.1111/j.1365-2559.2009.03408.x. **PubMed PMID: 19912369.**
23. Godar S, **Ince TA**, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, McAllister SS, Jacks T, Weinberg RA. Growth-Inhibitory and Tumor-Suppressive Functions of p53 Depend on Its Repression of CD44 Expression. 11; 134(1):62-73; **Cell, 2008**
24. McAllister SS, Gifford AM, Greiner AI, Kelleher SP, Saelzler MP, **Ince TA**, Reinhardt F, Harris LN, Hylander BL, Repasky EA, Weinberg RA. Systemic endocrine instigation of indolent tumor growth requires osteopontin. 13; 133(6):994-1005; **Cell, 2008**
25. Lerou PH, Yabuuchi A, Huo, H Takeuchi A, Shea J, Cimini T, **Ince TA**, Ginsburg SE, Racowsky C, and Daley GQ. Human Embryonic Stem Cell Derivation from Poor-Quality Embryos. 26:212-4; **Nat Biotechnol., 2008**
26. Park IH, Zhao R, West JA, Yabuuchi Am, Huo H, **Ince TA**, Lerou PH, Lensch MW, and Daley GQ. Reprogramming of human somatic cells to pluripotency with defined factors. 451:141-6; **Nature, 2008**
27. **Ince TA**, Richardson AL, Bell G, Saitoh M, Godar S, Karnoub AE, Iglehart JD and Weinberg RA. Transformation of distinct human breast epithelial cell types leads to different tumor phenotypes. 12(2):160-170; **Cancer Cell, 2007**

Curriculum Vitae

Tan A. Ince, M.D., Ph.D.

28. Witkiewicz AK, Hecht JL, Cviko A, McKeon FD, **Ince TA**, Crum CP. Microglandular hyperplasia: a model for the de novo emergence and evolution of endocervical reserve cells. 36(2):154-61; **Hum Pathol., 2005**
29. Dinulescu T, **Ince TA**, Quade BJ, Crowley D and Jacks T. Role of Oncogenic K-RAS in the Development of Endometriosis and Endometrioid Ovarian Adenocarcinoma. 11(1):63-70; **Nat Med., 2005**
30. Hecht JL, **Ince TA**, Baak JP, Baker HE, Ogden MW, Mutter GL. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. 18(3):324-30; **Mod Pathol., 2005**
31. Moore SD, Herrick SR, **Ince TA**, Kleinman MS, Cin PD, Morton CC, Quade BJ. Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF. 64(16):5570-7 **Cancer Res., 2004**
32. Watnick RS, Cheng YN, Rangarajan A, **Ince TA**, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. 3(3):219-31; **Cancer Cell, 2003**
33. **Ince TA**, Cviko AP, Quade BJ, Yang A, McKeon FD, Mutter GL, Crum CP. p63 coordinates anogenital modeling and epithelial cell differentiation in the developing female urogenital tract. 161(4):1111-7; **AM J Pathol., 2002**
34. Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP, **Ince TA**, McKeon FD, Cordon-Cardo C. Loss of p63 expression is associated with tumor progression in bladder cancer. 161(4):1119-206; **AM J Pathol., 2002**
35. Johnson RA, **Ince TA**, Scotto KW. Transcriptional repression by p53 through direct binding to a novel DNA element. 276(29):27716-20; **J Biol Chem., 2001**
36. Lin Y, **Ince TA**, Scotto KW. Optimization of a versatile in vitro transcription assay for the expression of multiple start site TATA-less promoters. 40(43):12959-66; **Biochemistry, 2001**
37. Mutter GL, **Ince TA**, Baak JPA, Kust GA, Zhou X-P, Eng C. Molecular identification of latent precancers in histologically normal endometrium. 61:4311-14; **Cancer Res., 2001**
38. **Ince TA**, Scotto KW. Stable integration of the P-glycoprotein promoter reproduces the endogenous overexpression phenotype: the role of MED-1. 56:2021-24; **Cancer Res., 1996**
39. **Ince TA**, Scotto KW. Differential utilization of multiple transcription start points accompanies the overexpression of the P-glycoprotein-encoding gene in Chinese hamster lung cells. 56:287-90; **Gene, 1995**
40. **Ince TA**, Scotto KW. A conserved downstream element defines a new class of RNA polymerase II promoters. 270:30249-52; **J Biol. Chem., 1995**

Curriculum Vitae

Tan A. Ince, M.D., Ph.D.

10. Other Works, Publications and Abstracts:

1. **Ince TA**, Ward JM, Valli VE, Sgro D, Nikitin AY, Loda M, Griffey SM, Crum CP, Crawford JM, Bronson RT, Cardiff RD: Do-it-yourself (DIY) pathology. 26:978-979; Nat Biochemical 2008
2. Lensch MW, **Ince TA**. The terminology of teratocarcinomas and teratomas. 25(11):1211; Nat Biochemical 2007
3. **Ince TA**, Witkiewicz AK, Crum CP, Letter to the Editor. 36(8):934-935; Hum. Pathology 2005
4. Barthold SW, Borowsky Ad, Brayton C, Bronson R, Cardiff RD, Griffey SM, **Ince TA**, Nikitin AY, Sundberg J, Valli VE, Ward JM. From whence will they come?- A perspective on the acute shortage of pathologists in biomedical research. 19(4):455-6; J Vet Diagn Invest. 2007
5. Crum CP, Drapkin R, Miron A, **Ince TA**, Muto M, Kindelberger DW, Lee Y. The distal fallopian tube: a new model for pelvic serous carcinogenesis. 19(1):3-9; Curr Opin Obstet Gynecol 2007
6. **Ince TA**, Crum CP. Telomerase: promise and challenge. 35(4):393-5 Hum Pathol. 2004
7. Nucci MR, Castrillion DH, Bai H, Quade BJ, **Ince TA**, Genest DR, Lee KR, Mutter GL, Crum CP. Biomarkers in diagnostic obstetric and gynecologic pathology; 10(2):55-68; Adv. Anat Pathol. 2003
8. **Ince TA**, Weinberg RA. Functional genomics and the breast cancer problem. 1:15-7; Cancer Cell 2002

11. Other Works Accepted for Publication: N/A

IV. Professional

12. Funded Research Performed:

Grant Title: Isolation and Characterization of Metastatic Breast Cancer Cell-of-Origin

Grant No.: N/A

Funding Agency: Breast Cancer Research Foundation

Grant Period: 10/01/09 - Continual

Role: PI

Grant Title: New Hormonal Treatment Strategy for Breast Cancer

Grant No.: N/A

Funding Agency: Women's Cancer Association

Grant Period: 06/01/14 – 05/31/15

Role: PI

Curriculum Vitae

Tan A. Ince, M.D., Ph.D.

Grant Title: Computational and Biological Deconvolution of Epigenomic Datasets

Grant No: RFA-RM-14-001 Ince, Houseman, and Harrell (PI)

Funding Agency: NIEHS

Grant Period: 09/24/14 – 09/18/15

Role: PI

Grant Title: Novel Culture System for Characterization of Ovarian Tumor Heterogeneity

Grant No: W81XWH-14-1-0160 (OC130649)

Funding Agency: CDMRP, Department of Defense (DOD) Ovarian Cancer Research Program (OCPR)
Resource Development Award

Grant Period: 08/01/14 - 08/14/17

Role: PI

Grant Title: Analysis of Heat Shock Factors in Tumor Stem Cell Regulation

Grant No.: 4BB12

Funding Agency: Bankhead-Coley Cancer Research Program

Grant Period: 11/01/2013 - 10/31/2015

Role: PI

Grant Title: Targeting the Histone Deacetylases, HDAC1 and HDAC7, in Breast and Ovarian Tumor-
Stem Cells

Grant No.: N/A

Funding Agency: Woman's Cancer Association

Grant Period: 05/11/13 – 05/31/15

Role: PI

Grant Title: Epigenomic Mapping in Human Tumor Stem Cells (PI-Robert Young)

Grant No: R01-CA146445-01

Funding Agency: WHITEHEAD INSTIT SC*NCI 5R01CA146445, Roadmap Epigenomics Project

Grant Period: 08/01/10 - 07/31/15

Role: Co-PI

Grant Title: Development of an In Vitro Culture System for Primary Adenoid Cystic Carcinoma Cells

Grant No.: N/A

Funding Agency: Adenoid Cystic Carcinoma Research Foundation

Grant Period: 07/01/10 – 10/31/11

Role: PI

Grant Title: Development of Human Tumor Cell Culture for Personalized Oncology

Grant No.: SB24 MT66142E

Funding Agency: Coulter Foundation

Grant Period: 01/1/13 – 11/30/14

Role: PI

Curriculum Vitae

Tan A. Ince, M.D., Ph.D.

Grant Title: The Role of Aberrant Splicing of EVI1 in Ovarian Cancer (PI – Gordon Mills)

Grant No.: N/A

Funding Agency: NIH

Activities to Promote Research Collaboration

Grant Period: 08/01/10 – 07/31/11

Role: Collaborator

Grant Title: Comparative phenotypic, functional, and molecular analysis of ESC & Ipsc

Grant No.: 1RC2HL102815-01

Funding Agency: Children’s Hospital Boston

Research and Research Infrastructure “Grand Opportunities” (RC2)

Grant Period: 09/01/10 – 08/31/11

Role: PI

Grant Title: Epigenetic Regulation of Normal and Transformed Breast Epithelial Cell Phenotype

Grant No.: W81XWH-08-1-0282

Funding Agency: CDMRP, Department of Defense (DOD) Breast Cancer Research Program (BCRP) IDEA Award

Grant Period: 12/10/10 – 06/30/12

Role: PI

Grant Title: A Fresh Approach to Identification and Characterization of Early Changes of Disease Associated with Ovarian Cancer (PI-Gordon Mills)

Grant No.: W81XWH-09-OCR-CONDEV

Funding Agency: Congressionally Directed Medical research Programs, Department of Defense (DOD) Ovarian Cancer Research Program (OCR-CONDEV), Consortium Development Award

Grant Period: 06/01/10 – 12/31/10

Role: Collaborator

13. Professional and Honorary Organizations

Center for Genomic Pathology, Member	2007-present
American Association for Cancer Research, Associate Member	1991-2008
American Association for the Advancement of Science, Member	1994-1996
The Harvey Society, New York, Member	1994-1996
New York Academy of Sciences, Member	1994-1996

14. Honors and Awards:

AACR Scholar-in-Training Award, 2006

Poster Award, Dana-Farber Harvard Cancer Center Breast Cancer Symposium, 2005

Curriculum Vitae

Tan A. Ince, M.D., Ph.D.

American Cancer Society, CRTG, Clinical Research Training Grant, ranked 1st, 2001

Vincent du Vigneaud Award of Excellence, Cornell University Graduate School, 1993

National Science Schools Entrance Exam, Turkey (ranked >99.99 percentile among 22,000 nationwide fifth grade students), 1974

15. Post-Doctoral:

Massachusetts Institute of Technology
Post-doctoral Fellow
Laboratory of Robert A. Weinberg
Whitehead Institute 09/2001-01/2007

Sloan-Kettering Cancer Center
Post-Doctoral Fellow in Molecular Biology
Laboratory of Kathleen Scotto
01/1996-06/1998

16. Other Professional Activities:

Local and National Presentations:

Invited speaker, 25th Annual Breast Cancer Think Tank, Grand Cayman Island, January 11-17, 2015

Invited speaker, 24th Annual Breast Cancer Think Tank, Bonaire, January 11-18, 2014

Invited speaker, Fred Hutchinson Cancer Research Center, 2014

Invited Speaker, University of Toronto Cancer Center, 2014

Invited Speaker, Ovarian Carcinoma Workshop, Cold Spring Harbour, 2014

Invited speaker, AACR Annual Meeting, Washington DC April 6-19, 2013

Invited speaker, 23rd Annual Breast Cancer Think Tank, Punta Cana, DR January 13-19, 2013

Moderator, World Stem Cell Summit, Palm Beach Convention Center, December 2012

Invited speaker, NCI–Breast Cancer Models Summit, Philadelphia, PA Nov. 29-30, 2012

Invited speaker, Innovative Tissue-Based Diagnostics, Cambridge Health-Tech Institute, Philadelphia, June 4 - 5, 2012

Invited speaker, Sixteenth Annual Laura Evans Memorial Breast Cancer Symposium, The Expedition Inspiration Fund for Breast Cancer Research (EIFBCR), Sun Valley, ID, March 7 - 11, 2012

Curriculum Vitae

Tan A. Ince, M.D., Ph.D.

Invited speaker, Pathway-Targeted Therapies in Cancer, Molecular Med TRI-CON
San Francisco, CA, February 23 - 25, 2011

Invited speaker, Nature Miami 2011 Winter Symposium: Epigenetics in Development and Disease,
Miami, FL, February 6 - 9, 2011

Invited speaker, Second Annual Symposium, Interdisciplinary Stem Cell Institute,
Miller School of Medicine University of Miami, Miami, FL, June 27-28, 2008.

Invited speaker, Society of Gynecologic Oncologists' 2008 Winter Meeting *New
Paradigms in Gynecologic Oncology Park City, UT*, February 15-17, 2008

Invited Speaker, Breast Cancer Seminar, Museum of Science, Boston, MA, October 28, 2007

Invited speaker, 14th SPORE Investigators' Workshop, Baltimore, MD, July 16-19,
2006

Invited speaker, American Association for Cancer Research 97th Annual Meeting,
Washington, DC, April 1-5, 2006

Invited speaker, Dana-Farber Harvard Cancer Center Ovarian/Gynecologic
Cancer Basic Research Seminars, February 6, 2006

Invited speaker, the MIT Center for Cancer Research (CCR) Focus Seminar,
Cambridge, MA, April 28, 2006

Guest, Sci-Tech Today, New England Cable Network (NECN)
http://www.whitehead.mit.edu/news/ontopic/stem_cells/stemcells.html March 26, 2006

Speaker, Dana-Farber Harvard Cancer Center Breast Cancer Symposium, Harvard
Club, Boston, MA, March 25, 2005

Invited speaker, San Antonio Breast Cancer Symposium, San Antonio, TX December
8-11, 2005

Invited speaker, Gordon Research Conference on Mammary Gland Biology, Salva
Regina University, Newport, RI, June 12-17, 2005

International Presentations:

Invited speaker, Gordon Research Conference on Mammary Gland Biology, Ciocco
Lucca, Italy, June 1-6, 2008

Invited speaker, Netherlands Cancer Institute, Amsterdam, Netherlands May 25,
2008

Curriculum Vitae

Tan A. Ince, M.D., Ph.D.

Invited speaker, 21st European Congress of Pathology, Precongress Meeting of the Working Group Gynecopathology, Istanbul, Turkey, September 8-13, 2007

Invited speaker, Cancer Stem Cell Workshop, Ontario, Canada, May 7-9, 2004

Review Panel and Committee Service

Peer Review Panel Member, Breast Cancer Research Program (BCRP) for the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP), 2013.

Peer Review Panel Member, Breast Cancer Research Program (BCRP) for the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP), 2009.

Panelist, WHO Technical Consultation on the Safety of Quinacrine When Used as a Method of Non-surgical Sterilization in Women, The Department of Reproductive Health and Research at World Health Organization, Geneva, Switzerland, 8-10 October 2008.

Patents Issued

- 1) Inventor: Ince TA and Weinberg RA
Title: Hormone Responsive Tissue Culture System and Uses Thereof.
US Patent No: 8252591
Assignee: Whitehead Institute and Brigham & Women's Hospital
Date Issued: August 28, 2012
Filed: May 6, 2005
This invention - a serum-free chemically-defined medium formulation - has been licensed and is available from a commercial vendor.

Patents Pending

- 1) Inventor: Ince TA (2013)
Title: CLASSIFICATION SYSTEM, METHODS AND KIT FOR CLASSIFYING, PREDICTING AND TREATING BREAST CANCER
Assignee: University of Miami
- 2) Inventors: Aster JC, Andrew P and Ince TA (2012)
Title: IN VITRO CULTURE CONDITIONS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
Assignee: Whitehead Institute and University of Miami

Curriculum Vitae

Tan A. Ince, M.D., Ph.D.

- 3) Inventor: Ince TA (2012)
Title: COMPOSITIONS AND METHODS FOR CULTURING CELLS FROM NORMAL TUBO-OVARIAN EPITHELIUM AND TUBO-OVARIAN TUMORS
Assignee: Whitehead Institute and Brigham & Women's Hospital
- 4) Inventor: Thong Ihn Lee, Richard A. Young, Ince TA (2011)
Title: MARKERS FOR AND METHODS OF TARGETING TUMOR STEM CELLS
Assignee: Whitehead Institute and University of Miami
- 5) Inventor: Ince TA and Weinberg RA (2005)
Title: Contribution of Target Cell Type to Epithelial Tumor Phenotypes.
Assignee: Whitehead Institute and Brigham & Women's Hospital
US utility application, USSN 11/123,612, May 5, 2005

V. Teaching

17. *Teaching Awards:* N/A

18. *Teaching Specialization:*

2010-present

Lecturer, Tumor Stem Cells and Basic Pathology graduate student seminars, Director: Kerry L. Burnstein, PhD, Graduate Program in Cancer Biology, U. of Miami

Preparation Time: 3 hours

Number of attendees: 10

Contact time with attendees: 5 hours

2002-2009

Lecturer, Interpreting the Endometrial Biopsy, Hands-on course

Directors: George L. Mutter, MD and Christopher P. Crum, MD

Department of Continuing Education, Harvard Medical School

Number of attendees: 40-50

Contact time with attendees: 12 hours

2002-2005

Lecturer, Biomarkers and Pathologic Diagnosis of Gynecologic Neoplasia Course

Director: Christopher P. Crum, MD

Department of Continuing Education, Harvard Medical School

Number of Attendees: 40-50

Contact time with attendees: 12 hours

19. *Thesis and Dissertation Advising/Post-doctoral Student Supervision:*

Curriculum Vitae

Tan A. Ince, M.D., Ph.D.

Mentor Ankita Thakkar, Ph.D Candidate	2010-Present
Thesis Committee Member Diana Azzam, Ph.D candidate	2012
Thesis Committee Chair Alexandra Besser, MD, Ph.D candidate	2012

VI. Service

20. University Committee and Administrative Responsibilities:

IAB-Personalized Medicine Monthly Meeting	2015-Present
Sylvester Comprehensive Cancer Center Scientific Steering Committee	2014-Present
Protocol Review Committee	05/2014-Present
Scientific Director, Tissue Bank Core Facility	12/2014-present
Director, Tumor Stem Cell Division	05/2010-present
Director, Live tumor Culture Core	12/2013-present
Grant Review Panel Member Braman Family Breast Cancer Institute Grants	2012
Member, Braman Family Breast Cancer Institute	05/2010-present